Skip to main content
Contact Us
Subscribe
E-Edition
75°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Baudax Bio, Inc.
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
May 12, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio to Present at the Sidoti Virtual Investor Conference
May 03, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Closing of $4 Million Public Offering
May 01, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Pricing of $4 Million Public Offering
April 26, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
April 25, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
April 24, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
March 27, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
February 23, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
January 24, 2023
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
December 08, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Closing of $5 Million Public Offering
December 06, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Pricing of $5 Million Public Offering
December 02, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Announces 1-for-40 Reverse Stock Split
November 30, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
November 08, 2022
From
Baudax Bio, Inc.
Via
GlobeNewswire
Tickers
BXRX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.